Related Experiment Video
Updated: Jun 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Management of atrial fibrillation in the elderly
1Division of Cardiology, Department of Medicine New York Medical College, Alhalla, New York, NY, USA. wsaronow@aol.com
Insights
Atrial fibrillation (AF) management involves immediate cardioversion for acute conditions and rate control with medications or pacemakers for persistent symptoms. Anticoagulation with warfarin or aspirin is crucial for stroke prevention in AF patients.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) increases mortality, stroke, and coronary events compared to sinus rhythm.
- Rapid ventricular rates in AF can lead to tachycardia-related cardiomyopathy.
Purpose of the Study:
- To outline current management strategies for atrial fibrillation.
- To detail treatment options for rapid ventricular rates and stroke prevention.
Main Methods:
- Review of established treatment guidelines for atrial fibrillation.
- Discussion of pharmacological and non-pharmacological interventions.
- Emphasis on anticoagulation protocols for stroke risk reduction.
Main Results:
- Immediate DC cardioversion is recommended for AF with acute myocardial infarction, ischemia, hypotension, heart failure, or syncope.
- Rate control can be achieved with beta-blockers, diltiazem, verapamil, or pacemakers.
- Warfarin (INR 2.0-3.0) is recommended for stroke prevention in high-risk AF patients; aspirin for low-risk or warfarin-contraindicated patients.
Conclusions:
- Treatment decisions for AF depend on clinical presentation, rate control, and stroke risk.
- Anticoagulation is paramount for preventing AF-related strokes.
- Cardioversion, rate control, and rhythm control strategies should be individualized.
Abstract:
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, diltiazem, or verapamil may be administered to slow immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds which are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in older patients, ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiar-rhythmic drugs. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should be treated with aspirin 325 mg daily.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Drug Dosing: Geriatric Patients
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Heart Failure V: Medical Management
